Among the 81 patients who had TMPRSS2:ERG fusion transcripts within their tumour tissue, 37 (45.7%) experienced biochemical recurrence, whereas among the 84 patients who had tumours that lacked fusion, only six (7.1%) experienced a relapse (odds ratio=10.9, 95% CI=4.3–27.9, P=10−7). Here, TMPRSS2 is linked to neoplasm.